Sarepta Therapeutics (SRPT) Stock Price

Sarepta Therapeutics Price

NASDAQ·CLOSED
14.69
​
Market closed

Over the last 19 years Sarepta Therapeutics grew revenue by 68.0% annually, reaching 2.20 B USD. For Sarepta Therapeutics, the net margin of -32.5% is up versus -59.7% a few years ago. The consensus 12-month price target for Sarepta Therapeutics is 25.00 USD, about 70.2% above where the stock trades today. Of 31 analysts, 12 rate the stock a buy — an overall Hold consensus.

Sarepta Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sarepta Therapeutics business model & stock analysis

Sarepta Therapeutics Inc is a biopharmaceutical company that was founded in 1980 in Cambridge, Massachusetts, USA. The company focuses on developing therapies for the treatment of rare genetic diseases, particularly muscular dystrophies. Sarepta's mission is to change the lives of patients with rare diseases by developing innovative therapies that can improve their lives. Business model: Sarepta Therapeutics has developed a successful business model in recent years, focusing on the development of innovative therapies for rare diseases. The company utilizes the latest research methods to develop tailored solutions based on the genetic basis of each disease. Various divisions: The various divisions of Sarepta Therapeutics are typically focused on the different diseases against which the company is developing therapies. The portfolio includes products and therapies for: - Duchenne muscular dystrophy - Limb-girdle muscular dystrophy - Congenital myotonic dystrophy - Pompe disease Products: Sarepta has several products on the market to treat patients with various genetic diseases. One of the most well-known products is Exondys 51, used for the treatment of Duchenne muscular dystrophy (DMD). Sarepta has also launched another DMD therapy called Vyondys 53, which is based on a different genetic mutation. In addition to these products, Sarepta has also conducted several clinical studies to test the effectiveness of therapies against other rare genetic diseases such as spinal muscular atrophy, FMlP deficiency, and others. Sarepta Therapeutics has made significant progress in recent years in the development of therapies for rare genetic diseases. The goal is to improve the lives of patients around the world by developing innovative therapies tailored to a genetic basis.

Frequently asked questions about Sarepta Therapeutics

The business model of Sarepta Therapeutics Inc revolves around developing and commercializing innovative RNA-based therapeutics for the treatment of rare genetic diseases. With a focus on Duchenne muscular dystrophy (DMD), Sarepta aims to provide transformative treatments that can positively impact the lives of patients. By continuously advancing their proprietary exon-skipping technology, Sarepta strives to develop exon-skipping therapies that help restore functional dystrophin protein production in DMD patients. Additionally, the company collaborates with other organizations and leverages its expertise to explore potential treatments for additional rare diseases. Sarepta Therapeutics Inc is dedicated to improving the lives of those affected by rare genetic disorders through its strategic business model.

Sarepta Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Sarepta Therapeutics Inc in the market include Biogen Inc, Pfizer Inc, and Vertex Pharmaceuticals Incorporated.

Sarepta Therapeutics Inc is a renowned biotechnology company specializing in the development and commercialization of innovative RNA-targeted therapeutics. Founded in 1980 and headquartered in Massachusetts, United States, Sarepta Therapeutics Inc has made significant contributions to genetic medicine research and development. With a strong focus on rare diseases, particularly Duchenne muscular dystrophy (DMD), the company's breakthrough drug, Exondys 51, has gained FDA approval and has helped improve the lives of patients with this debilitating condition. Sarepta Therapeutics Inc continuously strives to advance scientific knowledge and deliver groundbreaking treatments to those in need.

Sarepta Therapeutics Inc has achieved several significant milestones. The company successfully obtained accelerated approval from the U.S. FDA for their first product, Exondys 51, which is a treatment for Duchenne muscular dystrophy (DMD). This approval marked a major breakthrough in the DMD treatment landscape. Sarepta also received approval for their second DMD therapy, Vyondys 53. The company has consistently focused on advancing innovative therapies for rare diseases and has made progress in expanding their pipeline with potential treatments for other muscular dystrophies and genetic diseases. Sarepta Therapeutics Inc continues to demonstrate their commitment to improving the lives of patients through their groundbreaking research and development efforts.

Sarepta Therapeutics Inc is primarily present in the United States.

Sarepta Therapeutics Inc is driven by its core values of innovation, patient focus, and scientific excellence. With a corporate philosophy that prioritizes advancing therapies for rare diseases, the company is committed to improving the lives of individuals living with genetic-based diseases. Sarepta Therapeutics Inc dedicates its efforts to developing transformative RNA-based therapies, utilizing proprietary technology platforms to address unmet medical needs. By collaborating with patients, healthcare professionals, and industry partners, Sarepta Therapeutics Inc aims to provide effective treatments and hope for those in need. The company's dedication to scientific rigor and patient-centricity underpins its mission to make a meaningful impact on the lives of patients and their families.

Analysts currently set an average price target of 25.11 USD for the Sarepta Therapeutics stock (median: 25.00 USD), implying +70.0 % versus the latest price. The consensus is based on 31 analyst ratings.

31 analysts currently rate the Sarepta Therapeutics stock: 12 recommend buying, 13 holding and 6 selling. For 2026, analysts expect Sarepta Therapeutics to generate revenue of 1.86 B USD and earnings per share of 4.07 USD.

Converted at the current exchange rate, the Sarepta Therapeutics share trades at 13.35 EUR (14.69 USD).

The Sarepta Therapeutics share (SRPT) is listed on 7 stock exchanges, including: NASDAQ (SRPT), London (0L35.L), SIX (Zürich) (AB3A.SW), Frankfurt (AB3A.F), München (AB3A.MU), Düsseldorf (AB3A.DU).

Sarepta Therapeutics Inc is an American biotechnology company focused on developing innovative therapies for the treatment of rare muscular diseases. The company is known for its groundbreaking therapies that help patients with Duchenne muscular dystrophy (DMD) and other rare pathological conditions of muscle tissue.

The expected revenue of Sarepta Therapeutics is 1.86 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sarepta Therapeutics is 426.47 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sarepta Therapeutics is currently 3.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sarepta Therapeutics stock.

The price-to-sales ratio (P/S) of Sarepta Therapeutics is currently 0.83. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sarepta Therapeutics stock.

The Eulerpool Quality Score for Sarepta Therapeutics is 5/10.

The ISIN of Sarepta Therapeutics is US8036071004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sarepta Therapeutics is A1J1BH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sarepta Therapeutics is SRPT. The ticker symbol is used to trade Sarepta Therapeutics shares on the stock exchange.

Fair ValueTerminal
12.63 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
2.63 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website sarepta.com
Currency
USD
Initial public offering
Jun 4, 1997
ISIN
US8036071004
Cusip
803607100
Sedol
B8DPDT7
Market capitalization
1.58 B USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
3.71
P/Ee 2027
9.90
P/Ee 2028
2,891.32
P/Ee 2029
-42.47
P/Ee 2030
-40.54
P/S
P/Se
0.83
EV/EBIT
—
P/B Ratio
1.39
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-32.72 %
Last updated Nov 19, 2026, 1:06 AM

Sarepta Therapeutics Ticker

DÜSSELDORF · AB3A.DUFRANKFURT · AB3A.FLONDON · 0L35.LLONDON STOCK EXCHANGE · 0L35.LMUNICH · AB3A.MUNASDAQ · SRPTSIX · AB3A.SW

Sarepta Therapeutics FIGI

SRPT:US · BBG000BCJ161SRPT:UA · BBG000BCJ1M3SRPT:UC · BBG000BCJ232SRPT:UN · BBG000BCJ312SRPT:UP · BBG000BCJ3K1SRPT:UB · BBG000BCJ4T0SRPT:UM · BBG000BCJ5S8SRPT:UX · BBG000BCJ6C3SRPT:UD · BBG000BCJ9N5SRPT:UW · BBG000BCJC58SRPT:UF · BBG000BCJCG6SRPT:VY · BBG000BCJD47